Study of efficacy and safety of Paclitaxel drug coated balloon in elderly patients with de novo coronary disease

• DOI: 10.3760/cma.j.issn.0254-9026.2016.08.009
• Publication Date: 2016-08-14
• Authors: Xue Yu; Wang Xinyue; Wenduo Zhang; Bing Liu; Dan Lu; Fucheng Sun; Fusui Ji
• Keywords: Mace

Objective To evaluate the efficacy and safety of Paclitaxel drug coated balloon (DCB) (SeQuent Please©) in an elderly patients with de novo coronary disease.

Methods We performed a retrospective study 158 consecutive (63 aged ≥65 yrs 95 <65 yrs) received DCB therapy Cath Lab Beijing Hospital. Clinical characteristic was recorded angiography analyzed quantitative angiography(QCA) software.

Results In group, more have hypertension (65.1% vs. 56.8%), atrial fibrillation (7.9% 2.1%), previous percutaneous intervention (PCI) history (44.4% 23.2%, P 0.05], late lumen loss (LLL) was(-0.09±0.50) mm. At 9 months follow-up, MACE rate group 1.6% 1.1% non-elderly TLR rates at 0.0% respectively (both P>0.05). No death observed either group.

Conclusions The on lesions is as good despite complex anatomy comorbidities.

Key words: Coronary diseases; Drug balloon; Treatment outcome